Notes

Possible aftereffect of lung fluid viscosity in beneficial end-expiratory pressure along with localised distribution of respiratory air flow inside acute respiratory hardship symptoms.
This study aimed to identify electrocardiographic (ECG) predictors of a prolonged His-ventricular (HV) interval in patients with type 1 myotonic dystrophy (DM1).

Patients with DM1 have an increased risk of sudden cardiac death. The presence of His-Purkinje system disease/prolonged HV interval (≥70ms) is associated with a higher risk of potentially life-threatening bradyarrhythmic events.

Electrophysiology studies (EPSs) were performed in all DM1 patients referred to 2 tertiary centers for routine cardiac assessment. In a subgroup of patients, the EPS was repeated at varying intervals.

A total of 154 patients (mean age 43.7 ± 13.3; 58.1% male) underwent 202 diagnostic EPSs. HV≥70ms was found on 58 EPSs (28.7%); 9 of 59 patients (15.2%) with PR<200ms and QRS interval<110ms on baseline ECG had an HV≥70ms on EPS. Among those with PR≥200ms and/or QRS interval≥100ms, only 33.9% had an HV≥70ms on EPS. There were 38 patients who underwent repeated EPS, in which 28.8% demonstrated a prolongation of the Hms do not have advanced His-Purkinje conduction system disease on EPS. Electrophysiology testing should be a mandatory part of screening for all patients to guide prophylactic pacemaker implantation.
The objective of this clinical trial was to evaluate the safety and effectiveness of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) (Abbott, Abbott Park, Illinois) for the treatment of drug-refractory, symptomatic paroxysmal atrial fibrillation (PAF).

Catheter ablation of atrial fibrillation (AF) is an established therapy for the treatment of PAF. Ablation technology is evolving with the primary goals of improving efficacy and safety of the procedure.

This was a multicenter single-arm trial evaluating a novel ablation catheter for the treatment of PAF. A total of 156 subjects were enrolled at 19 sites in the United States, Europe, and Australia. U0126 The primary safety end point was the rate of device- or procedure-related serious adverse events occurring within 7days. The primary effectiveness end point was acute success defined as pulmonary vein isolation at 30min after ablation. Two descriptive end points were prospectively captured 1) 1-year freedom from recurrence of symptomatic AF, atrial flutter (AFL), and atrial tachycardia (AT) lasting≥30s without a new or increased dose of class I/III antiarrhythmic drugs; and 2) 1-year drug-free success defined by the absence of any recurrent AF/AFL/AT lasting≥30s without using class I/III antiarrhythmic drugs.

Primary safety events occurred in 4.7% of patients (95% confidence interval [CI] 2.23% to 8.64%), and the procedure was acutely successful in 98.0% of patients (95%CI 94.95% to 99.46%). According to Kaplan-Meier estimates at 1 year, 82.2% (95%CI 74.7% to 87.6%) were free from symptomatic recurrence, and 1-year drug-free success was 68.2% (95%CI 59.9% to 75.1%).

The TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ is safe and effective for the treatment of paroxysmalAF.
The TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ is safe and effective for the treatment of paroxysmal AF.
This study sought to identify electrocardiographic (ECG) and clinical predictors of sudden cardiac arrest (SCA) in sarcoidosis.

Sudden cardiac death (SCD) is the leading cause of death in cardiac sarcoidosis (CS) and may be the earliest manifestation of disease. Widespread or repeated advanced imaging is a challenging solution to this problem. ECG is an affordable and widely accessible modality that could help guide diagnostic approaches and risk stratification.

Data were obtained from the National Inpatient Sample (2005-2017) using International Classification of Diseases, Ninth Revision and 10th Revision, Clinical Modification. The primary outcome was to identify predictors of SCA, whereas predictors of SCA in young individuals and those with normal ventricular function served as secondary measures. Furthermore, temporal trends in sarcoidosis as well as SCA were also analyzed. Logistic regression analysis was used to calculate odds ratios, following which a multivariable regression was used to adjust resence of a normal ECG does not reflect a low risk of SCA.
The aim of the study was to report the efficacy of left bundle branch pacing (LBBP) in the management of left bundle branch block (LBBB)-induced cardiomyopathy (LIC).

Chronic LBBB is known to cause mechanical dyssynchrony and cardiomyopathy. Hyperresponse to cardiac resynchronization therapy (CRT) with biventricular pacing (BVP) is a hallmark of LIC. LBBP has recently shown promise as an alternative to BVP.

Patients undergoing CRT between 2018 and 2020 were retrospectively screened, and those who met the criteria for LIC were included in the study. Duration of LBBB, CRT type, and response were documented. Pacing parameters, and electrocardiographic and echocardiographic data were collected.

Possible LIC was identified in 17 of 159 patients undergoing CRT and LBBP was successfully performed in 13 patients. Duration of LBBB before left ventricular dysfunction was 4.2 ± 3.9 years. Temporary His bundle pacing corrected underlying LBBB in all patients. During LBBP, there was significant reduction in QRS duration (167.8 ± 11.6ms to 110.4 ± 13.1ms; p<0.0001) and repolarization parameters of QTc, Tpeak-Tend, and Tpeak-Tend/QTc ratio. LBBP threshold and R waves at implant were 0.53 ± 0.21 V/0.5ms and 11.7 ± 7.1mV and remained stable. Cardiac magnetic resonance imaging showed no evidence of scar (n=8). During follow-up, left ventricular ejection fraction improved from 30.4 ± 6.6% to 57.4 ± 4.7% (p<0.0001) and New York Heart Association functional class improved from 3.1 ± 0.3 to 1.2 ± 0.4 (p<0.0001) compared with baseline.

LBBP is a reasonable option for CRT in patients with LIC, as it provides low and stable capture threshold with complete correction of underlying electrical and mechanical abnormalities associated with LBBB.
LBBP is a reasonable option for CRT in patients with LIC, as it provides low and stable capture threshold with complete correction of underlying electrical and mechanical abnormalities associated with LBBB.
Read More: https://www.selleckchem.com/products/U0126.html